Lonza and Bioqube Ventures to scale biologics and small molecules

Related Articles

FormattedPicture

BUSINESS NEWS

Lonza is seeing a portfolio shift to premium nutraceutical products, as well as sustained demand for specialty capsules. The Switzerland-based group’s 2021... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

Digestive health has gained importance over the past years due to the COVID-19 pandemic, but it continues to evolve. For example, there is an increase in delivery... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

Health claims play a crucial role in communicating with consumers but different regional approaches reveal a fractured scene. Experts from Gencor, Lonza,... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

The gaps between the nutraceutical and pharmaceutical spaces are diminishing as companies continue to maximize the market potential for their ingredients. However, key... Read More

FormattedPicture

BUSINESS NEWS

Chr. Hansen and Lonza’s joint venture Bacthera and microbiome therapeutics company Seres Therapeutics are teaming up to manufacture SER-109, Seres’ lead... Read More

trans